Maintaining Data Integrity: Understanding FDA ALCOA Guidance

Did you know that lack of data integrity has been a top reason for FDA Drug GMP warning letters?*

In their 2018 Questions and Answers guidance on the implementation of their 21 CFR Part 11 data integrity rule, the FDA use the acronym ALCOA, where they define good data integrity practice as creating records that are attributable to the technician carrying out the testing, are legible, are created contemporaneously, original and accurate.

ALCOA attributable legible contemporaneously recorded original accurate

Attributable

Attributable can be interpreted to mean that records should include an electronic ‘signature’ to link them to the instrument/person that made the measurement and they should also include a reference to the water system being tested and the date and time it was taken. This implies electronic signatures for users signed on to the system. Control over electronic signature format can be site specific and is usually controlled by the IT department using Microsoft Active Directory controls. Ideally the on-line instrumentation should be configured to follow Active Directory controls to ensure correct electronic signature format according to the site-specific rules.

Legible records

The record of course is required to be legible, which implies that hand-written records are not acceptable. The FDA goes on to suggest that electronic records should be stored in a format that is open and can be read on many computing formats so that it will be accessible and readable for years to come. The FDA recommends typical formats such as PDF, XML or SGML.

Contemporaneous

The word contemporaneously implies that the electronic records should be created immediately when the sample is measured, implying that manual transcription of paper records is not good practice and that collating paper records and then manually transcribing them into electronic format at a later time or date is not good practice either.

Original

Naturally there is a danger with every transcription of test results from one form to another. Even scanning multiple paper records into electronic format runs the risk of duplication or missed scans. So the FDA recommends that the electronic record should be the original record created when the test was completed. Obviously, manually transcribed records are the riskiest, attracting the biggest opportunity for human error.

Accurate records

Finally the A in ALCOA. Naturally the electronic records should be accurate. This implies that the process for capturing those electronic records should be robust, i.e. manual calculations and manual data entry where opportunities for human error exist should be avoided. Electronic records generated by on-line instruments should contain information that links the data to the instrument used to make the measurement and the time and date of the measurement.

Our instruments are designed to facilitate ALCOA guidance. Discover the details here:

Products Designed for ALCOA Guidance

QC Step: Raw Material

Instrument

Application

Regulation

 A

 L

 C

 O

 A

ANATEL PAT700 TOC Analyzer   On-line Water for Injection (WFI), Purified Water (PW), Total Organic Carbon (TOC), Temperature and Conductivity

USP <643>

USP <645>

EP 2.2.44

Multi-level, Individual User Name and Password for all users Legible secure PDF export for Alarm Trail, Audit Trail, Measurement Results Secure PDF created on day of sample analysis Original electronic record created directly from the instrument Original electronic record created directly from the instrument

QC Step: Production

Instrument

Application

Regulation

 A

 L

 C

 O

 A

Vi-CELL BLU Cell Viability Analyzer  Mammalian cell viability and concentration USP <1046> Multi-level, Individual User Name and Password for all users Legible secure PDF export for measurement Results Secure data records stored and tracked at time of measurement Original electronic record created directly from the instrument SOP parameters pre-programed into the instrument and automated
Vi-CELL MetaFLEX Bioprocessing Monitor  Mammalian cell bioreactor media health   Multi-level, Individual User Name and Password for all users Legible reports can be printed or viewed on the instrument Secure data records stored and tracked at time of measurement Original electronic record created directly from the instrument SOP parameters pre-programed into the instrument and automated
MET ONE 3400+ Air Particle Monitor  Routine environmental monitoring (air particulates) in sterile manufacturing
cleanrooms
EU GMP Annex 1, CGMP, ISO 14644-1 & -2 Multi-level, Microsoft Active Directory Username and Password control creates unique electronic signatures for users Legible secure PDF export for Measurement Results including metadata Secure PDF created on day of sample analysis Original electronic record created directly from the instrument SOP parameters pre-programed into the instrument and automated
MET ONE Facility Monitoring System  Sterile manufacturing cleanroom continuous air particulate monitoring EU GMP Annex 1, CGMP, ISO 14644-2 Multi-level, Individual User Name and Password for all users Legible secure PDF export for Alarm Trail, Audit Trail, Measurement Results Secure data records stored in database at time of measurement Original electronic record created directly inside the counter Your SOPs and sampling maps uploaded into the counter with version control. Completed records reviewed and approved for accuracy in the counter remotely via web-browser. No manual counter configuration or sample location entry.

QC Step: Final Product Testing

Instrument

Application

Regulation

 A

 L

 C

 O

 A

HIAC 9703+ Liquid Particle Counter  Final product sub-visible particulate counting in parenteral drug products

USP <787>

USP <788>

USP <789>

Multi-level, individual User Name and Password for all users Legible, secure PDF export for Alarm Trail, Audit Trail, Measurement Results
Secure PDF created on day of sample analysis Original electronic record created directly from the instrument SOP parameters pre-programed into the instrument and automated
Multisizer 4e Coulter Counter  Final product visible particulate counting in parenteral drug products  

Multi-level, individual, user name and password for all users

Legible secure PDF export for Audit Trail, Measurement Results Secure PDF created on day of sample analysis Original electronic record created directly from the instrument SOP parameters pre-programed into the instrument and automated

*Pharmaceutical Online, An Analysis Of FDA FY2018 Drug GMP Warning Letters By Barbara Unger, Unger Consulting Inc., https://www.pharmaceuticalonline.com/doc/an-analysis-of-fda-fy-druggmp-warning-letters-0003, published February 1, 2019

Reflection paper on expectations for electronic source data and data transcribed to electronic data collection tools in clinical trials By GCP Inspectors Working Group https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/reflection-paper-expectations-electronic-source-datadata- transcribed-electronic-data-collection_en.pdf, published June 09, 2010

Content and Resources

Filter by:
Resource Type
Registros electrónicos de control de calidad para el cumplimiento de 21 CFR parte 11 Este documento describe c&oacute;mo se pueden optimizar los instrumentos de control de calidad para uso farmac&eacute;utico, ayudando a mejorar la integridad de los datos en el registro electr&oacute;nico final.
21 CFR Part 11 Data Integrity for On-line WFI Instruments This application note takes a look at how quality-critical on-line Total Organic Carbon (TOC) and conductivity instrumentation for WFI (water for injection) quality control can be configured to help companies comply with the FDA&rsquo;s expectations on data integrity, including the use of Microsoft Active Directory and PDF data export.
Automatización del control de calidad biofarmacéutica para reducir costes y mejorar la integridad de los datos Este documento analiza cuatro procedimientos comunes de control de calidad y c&oacute;mo la automatizaci&oacute;n puede ayudar a mejorar la integridad de los datos reduciendo las oportunidades de error humano, a la vez que se ahorra tiempo y se reducen los costes operativos. Los cuatro procedimientos de control de calidad que se describen en este documento forman un hilo com&uacute;n en la industria de la fabricaci&oacute;n biofarmac&eacute;utica y son: pruebas de calidad del agua, monitorizaci&oacute;n ambiental rutinaria de sala limpia, recuento de c&eacute;lulas biol&oacute;gicas y pruebas de viabilidad y pruebas finales de part&iacute;culas inyectables de f&aacute;rmacos.
Optimización del flujo de trabajo Eficiencia de la monitorización ambiental rutinaria de sala limpia Este documento examina un programa de monitorizaci&oacute;n ambiental cuidadosamente dise&ntilde;ado y bien ejecutado que pone a prueba los controles establecidos para mantener la sala limpia seg&uacute;n los est&aacute;ndares requeridos de Buenas Pr&aacute;cticas de Fabricaci&oacute;n (p. ej., BPFA, EUBPF, y PIC/S).
Monitorización ambiental rutinaria de sala limpia – Guía de la FDA sobre 21 CFR Parte 11 Integridad de los datos Este documento examina el riesgo de error con los PNT que se implementan manualmente. Existe tecnolog&iacute;a disponible para mitigar este problema y hacer que los programas sean m&aacute;s fiables, lo que reduce el impacto en la integridad de los datos y tambi&eacute;n ayuda al movimiento de la industria hacia la monitorizaci&oacute;n ambiental por parte del personal de producci&oacute;n en la sala limpia.

Helpful Links

 

Talk To An Expert